Nobuyoshi Kosaka
Publication Activity (10 Years)
Years Active: 2020-2024
Publications (10 Years): 7
Publications (10 Years): 7
Tokyo Medical University
Waseda University (PHD)
Affiliation History
Tokyo Medical University
Apr 01 2019
Japan
Associate Professor :: Department of Mocecular and Cellular Medicine
University of Oxford
United Kingdom
JSPS Postdoctoral Fellowships for Research Abroad :: Department of Zoology
University of Oxford
United Kingdom
Visiting Scientist :: Department of Zoology
National Cancer Center Research Institute
Japan
Staff Scientist :: Molecular and Cellular Medicine
National Cancer Center Research Institute
Japan
Research Resident :: Section for Studies on Metastasis
National Cancer Center Research Institute
Japan
Postdoctoral Fellow :: Section for Studies on Metastasis
National Cancer Center Research Institute
Japan
JSPS Research Fellow (Postdoctoral) :: Section for Studies on Metastasis
Waseda University
Japan
JSPS Research Fellow (Doctoral) :: Graduate School of Science and Engineering
Education History
Waseda University
Japan
PHD :: Graduate School of Science and Engineering
Waseda University
Japan
MSC :: Graduate School of Science and Engineering
Waseda University
Japan
BSC :: Department of Biology
Publications
- Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu MasudaReal-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
- Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu MasudaReal-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
- Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu MasudaReal-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
- Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu MasudaReal-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) (2024)
- Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Nobuyoshi Kosaka, Kentaro Tajima, Norikazu MasudaReal-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast cancer (Tokyo, Japan) 31 (4) (2024)
- Nobuyoshi Kosaka, Nobuyoshi Kosaka, Yurika Sawa, Yusuke Yamamoto, Kagenori Ito, Tomofumi Yamamoto, Takahiro Kimura, Shin Egawa, Takahiro Ochiya
- Nobuyoshi Kosaka, Nobuyoshi Kosaka, Yurika Sawa, Kagenori Ito, Takahiro Kimura, Shin Egawa, Takahiro Ochiya, Yusuke Yamamoto